{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T08:55:57Z","timestamp":1790672157001,"version":"4.1.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T00:00:00Z","timestamp":1780704000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T00:00:00Z","timestamp":1780704000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Faculdade Israelita De Ci\u00eancias Da Sa\u00fade Albert Einstein"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Chimeric antigen receptor T-cell (CAR-T) therapy has emerged as a highly effective treatment for refractory and relapsed hematologic malignancies. Despite its clinical benefits, CAR-T therapy is associated with a unique toxicity profile, including cytokine release syndrome (CRS), immune effector cell\u2013associated neurotoxicity syndrome (ICANS), and prolonged immunosuppression. Oral complications in this population remain underreported. This retrospective case series was aimed at describing oral manifestations and dental management in patients undergoing CAR-T therapy at a tertiary referral center. Medical and dental records of ten patients treated with CAR-T therapy between 2024 and 2025 were reviewed. Demographic data, underlying hematologic diagnoses, CAR-T-related toxicities, and oral findings were analyzed descriptively. The main oral manifestations observed were xerostomia, opportunistic infections, dental pain, and dysgeusia. Oral care focused on symptom control, prevention of secondary infections, and supportive oral management during periods of severe immunosuppression. These findings suggest that early dental involvement may contribute to supportive care strategies, particularly for the detection and management of opportunistic infections and dental infectious foci in neutropenic patients. Standardized oral assessment protocols and preventive dental measures may contribute to supportive clinical management and symptom monitoring in this patient population.<\/jats:p>","DOI":"10.1007\/s00520-026-10824-6","type":"journal-article","created":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T05:27:02Z","timestamp":1780723622000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Oral manifestations and dental management in patients undergoing CAR-T cell therapy: a retrospective observational study"],"prefix":"10.1007","volume":"34","author":[{"given":"Fernanda","family":"de Paula Eduardo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luiza Deitos","family":"Menti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana Henriques","family":"Ferreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle Lima Correa","family":"de Carvalho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"de Paula Novaes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz Helena","family":"da Silva Martins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucila Nassif","family":"Kerbauy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nelson","family":"Hamerschlak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Let\u00edcia Mello","family":"Bezinelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,6]]},"reference":[{"key":"10824_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.oraloncology.2022.106030","volume":"133","author":"LT Galaniha","year":"2022","unstructured":"Galaniha LT, Nolden AA (2022) The role of saliva in taste dysfunction among cancer patients: mechanisms and potential treatment. Oral Oncol 133:106030. https:\/\/doi.org\/10.1016\/j.oraloncology.2022.106030","journal-title":"Oral Oncol"},{"key":"10824_CR2","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.950923","volume":"13","author":"Y Li","year":"2022","unstructured":"Li Y, Ming Y, Fu R, Li C, Wu Y, Jiang T, Li Z, Ni R, Li L, Su H, Liu Y (2022) The pathogenesis, diagnosis, prevention, and treatment of CAR-T cell therapy-related adverse reactions. Front Pharmacol 13:950923. https:\/\/doi.org\/10.3389\/fphar.2022.950923","journal-title":"Front Pharmacol"},{"issue":"4","key":"10824_CR3","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00459-7","volume":"11","author":"RC Sterner","year":"2021","unstructured":"Sterner RC, Sterner RM (2021) CAR-T cell therapy: current limitations and potential strategies. Blood Cancer J 11(4):69. https:\/\/doi.org\/10.1038\/s41408-021-00459-7","journal-title":"Blood Cancer J"},{"key":"10824_CR4","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-023-00929-0","volume":"13","author":"S Sidana","year":"2023","unstructured":"Sidana S, Hosoya H, Jensen A et al (2023) Bendamustine vs fludarabine\/cyclophosphamide lymphodepletion prior to BCMA CAR-T cell therapy in multiple myeloma. Blood Cancer J 13:158. https:\/\/doi.org\/10.1038\/s41408-023-00929-0","journal-title":"Blood Cancer J"},{"issue":"2","key":"10824_CR5","doi-asserted-by":"publisher","DOI":"10.3390\/cells13020146","volume":"13","author":"C Lonez","year":"2024","unstructured":"Lonez C, Breman E (2024) Allogeneic CAR-T therapy technologies: has the promise been met? Cells 13(2):146. https:\/\/doi.org\/10.3390\/cells13020146","journal-title":"Cells"},{"key":"10824_CR6","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1303935","volume":"14","author":"B Lickefett","year":"2023","unstructured":"Lickefett B, Chu L, Ortiz-Maldonado V, Warmuth L, Barba P, Doglio M, Henderson D, Hudecek M, Kremer A, Markman J, Nauerth M, Negre H, Sanges C, Staber PB, Tanzi R, Delgado J, Busch DH, Kuball J, Luu M, J\u00e4ger U (2023) Lymphodepletion \u2014 an essential but undervalued part of the chimeric antigen receptor T-cell therapy cycle. Front Immunol 14:1303935. https:\/\/doi.org\/10.3389\/fimmu.2023.1303935","journal-title":"Front Immunol"},{"key":"10824_CR7","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/s41571-023-00754-1","volume":"20","author":"KM Cappell","year":"2023","unstructured":"Cappell KM, Kochenderfer JN (2023) Long-term outcomes following CAR T-cell therapy: what we know so far. Nat Rev Clin Oncol 20:359\u2013371. https:\/\/doi.org\/10.1038\/s41571-023-00754-1","journal-title":"Nat Rev Clin Oncol"},{"issue":"12","key":"10824_CR8","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1089\/jir.2021.0057","volume":"41","author":"R Dong","year":"2021","unstructured":"Dong R, Jiang S, Chen Y, Ma Y, Sun L, Xing C, Zhang S, Yu K (2021) Prognostic significance of cytokine release syndrome in B-cell hematologic malignancies patients after chimeric antigen receptor T-cell therapy. J Interferon Cytokine Res 41(12):469\u2013476. https:\/\/doi.org\/10.1089\/jir.2021.0057","journal-title":"J Interferon Cytokine Res"},{"issue":"4","key":"10824_CR9","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2022.13478","volume":"24","author":"L Chen","year":"2022","unstructured":"Chen L, Xie T, Wei B, Di DL (2022) Current progress in CAR-T cell therapy for tumor treatment. Oncol Lett 24(4):358. https:\/\/doi.org\/10.3892\/ol.2022.13478","journal-title":"Oncol Lett"},{"issue":"2","key":"10824_CR10","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1097\/SPC.0000000000000540","volume":"15","author":"C Duncan","year":"2021","unstructured":"Duncan C, Redding SW (2021) Mucositis: pathogenesis and treatment. Curr Opin Support Palliat Care 15(2):125\u2013129. https:\/\/doi.org\/10.1097\/SPC.0000000000000540","journal-title":"Curr Opin Support Palliat Care"},{"issue":"Suppl 1","key":"10824_CR11","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1590\/S1413-81232010000700016","volume":"15","author":"FL Hespanhol","year":"2010","unstructured":"Hespanhol FL, Tinoco EMB, Teixeira HGC, Falabella MEV, Assis NMSP (2010) Buccal manifestations in patients submitted to chemotherapy. Cien Saude Colet 15(Suppl 1):1085\u20131094. https:\/\/doi.org\/10.1590\/S1413-81232010000700016","journal-title":"Cien Saude Colet"},{"key":"10824_CR12","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1146\/annurev-med-062915-115435","volume":"67","author":"SM Jaglowski","year":"2016","unstructured":"Jaglowski SM, Porter DL (2016) CAR T-cell therapy: a new era in cellular therapy. Annu Rev Med 67:225\u2013238. https:\/\/doi.org\/10.1146\/annurev-med-062915-115435","journal-title":"Annu Rev Med"},{"issue":"5","key":"10824_CR13","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1002\/cncr.22484","volume":"109","author":"DM Keefe","year":"2007","unstructured":"Keefe DM et al (2007) Updated clinical practice guidelines for the prevention and treatment of mucositis. Cancer 109(5):820\u2013831. https:\/\/doi.org\/10.1002\/cncr.22484","journal-title":"Cancer"},{"key":"10824_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2024.112312","volume":"135","author":"M Elmarasi","year":"2024","unstructured":"Elmarasi M, Elkonaissi I, Elsabagh AA, Elsayed E, Elsayed A, Elsayed B, Elmakaty I, Yassin M (2024) CAR-T cell therapy: efficacy in management of cancers, adverse effects, dose-limiting toxicities and long-term follow up. Int Immunopharmacol 135:112312. https:\/\/doi.org\/10.1016\/j.intimp.2024.112312","journal-title":"Int Immunopharmacol"},{"key":"10824_CR15","doi-asserted-by":"publisher","DOI":"10.1093\/chemse\/bjab031","volume":"46","author":"AA Sarkar","year":"2021","unstructured":"Sarkar AA, Delay ER, Delay RJ (2021) Cyclophosphamide-induced inflammation of taste buds and cytoprotection by amifostine. Chem Senses 46:bjab031. https:\/\/doi.org\/10.1093\/chemse\/bjab031","journal-title":"Chem Senses"},{"key":"10824_CR16","first-page":"223","volume":"23","author":"S Elad","year":"2015","unstructured":"Elad S et al (2015) Basic oral care for hematology-oncology patients and hematopoietic stem cell transplantation recipients: a position paper from the joint task force of the Multinational Association of Supportive Care in Cancer\/International Society of Oral Oncology (MASCC\/ISOO) and the European Society for Blood and Marrow Transplantation (EBMT). Support Care Cancer 23:223\u2013236","journal-title":"Support Care Cancer"},{"issue":"Suppl 3","key":"10824_CR17","first-page":"34","volume":"27","author":"S Vokurka","year":"2021","unstructured":"Vokurka S et al (2021) Oral complications of cancer therapy: overview and practical recommendations. Oral Dis 27(Suppl 3):34\u201342","journal-title":"Oral Dis"},{"key":"10824_CR18","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1016\/j.clnesp.2021.03.006","volume":"43","author":"IMV Silva","year":"2021","unstructured":"Silva IMV, Donaduzzi LC, Perini CC, Couto SAB, Werneck RI, de Ara\u00fajo MR, Kurahashi M, Johann ACBR, Azevedo-Alanis LRA, Vieira AR, Couto-Souza PH (2021) Association of xerostomia and taste alterations of patients receiving antineoplastic chemotherapy: a cause for nutritional concern. Clin Nutr ESPEN 43:532\u2013535. https:\/\/doi.org\/10.1016\/j.clnesp.2021.03.006","journal-title":"Clin Nutr ESPEN"},{"issue":"9 Suppl","key":"10824_CR19","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1002\/cncr.20162","volume":"100","author":"ST Sonis","year":"2004","unstructured":"Sonis ST et al (2004) Perspectives on cancer therapy-induced mucosal injury: pathogenesis, measurement, epidemiology, and consequences for patients. Cancer 100(9 Suppl):1995\u20132025","journal-title":"Cancer"},{"key":"10824_CR20","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","volume":"15","author":"SS Neelapu","year":"2018","unstructured":"Neelapu SS et al (2018) Chimeric antigen receptor T-cell therapy \u2014 assessment and management of toxicities. Nat Rev Clin Oncol 15:47\u201362","journal-title":"Nat Rev Clin Oncol"},{"issue":"2","key":"10824_CR21","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","volume":"124","author":"DW Lee","year":"2014","unstructured":"Lee DW et al (2014) Current concepts in the diagnosis and management of cytokine release syndrome. Blood 124(2):188\u2013195","journal-title":"Blood"},{"key":"10824_CR22","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/571739","volume":"2015","author":"C Zimmermann","year":"2015","unstructured":"Zimmermann C, Meurer MI, Grando LJ, Del Moral J\u00c2G, Rath IBS, Tavares SS (2015) Dental treatment in patients with leukemia. J Oncol 2015:571739. https:\/\/doi.org\/10.1155\/2015\/571739","journal-title":"J Oncol"},{"key":"10824_CR23","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-025-09845-4","volume":"33","author":"Y Zadik","year":"2025","unstructured":"Zadik Y, Raber-Durlacher JE, Epstein JB et al (2025) MASCC\/ISOO clinical practice statement: dental evaluation and management prior to treatment for hematologic malignancies and CAR T-cell therapy. Support Care Cancer 33:853. https:\/\/doi.org\/10.1007\/s00520-025-09845-4","journal-title":"Support Care Cancer"},{"issue":"4","key":"10824_CR24","first-page":"256","volume":"33","author":"JB Epstein","year":"2025","unstructured":"Epstein JB, Parker IR, Anand S (2025) Patient-reported evaluation of oral\/dental health in oncology care\u2014a need and opportunity to support medically necessary oral care needs. Support Care Cancer 33(4):256","journal-title":"Support Care Cancer"},{"issue":"10","key":"10824_CR25","first-page":"15","volume":"9","author":"E Somay","year":"2025","unstructured":"Somay E et al (2025) Oral toxicities following CAR T-cell therapy: an overlooked clinical reality. Acta Scientific Dental Sciences 9(10):15\u201328","journal-title":"Acta Scientific Dental Sciences"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-026-10824-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-026-10824-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-026-10824-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T18:02:57Z","timestamp":1784052177000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-026-10824-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,6]]},"references-count":25,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["10824"],"URL":"https:\/\/doi.org\/10.1007\/s00520-026-10824-6","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,6]]},"assertion":[{"value":"24 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"CAAE: 94925125.9.0000.007.","order":1,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.During the preparation of this manuscript, the authors used Gemini AI solely to improve language and readability. After using this tool, the authors carefully reviewed and edited the content and take full responsibility for the final version of the manuscript.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"621"}}